mTOR is a key modulator of ageing and age-related disease

Simon C. Johnson, Peter S. Rabinovitch and Matt Kaeberlein ()
Additional contact information
Simon C. Johnson: University of Washington
Peter S. Rabinovitch: University of Washington
Matt Kaeberlein: University of Washington

Nature, 2013, vol. 493, issue 7432, 338-345

Abstract: Abstract Many experts in the biology of ageing believe that pharmacological interventions to slow ageing are a matter of 'when' rather than 'if'. A leading target for such interventions is the nutrient response pathway defined by the mechanistic target of rapamycin (mTOR). Inhibition of this pathway extends lifespan in model organisms and confers protection against a growing list of age-related pathologies. Characterized inhibitors of this pathway are already clinically approved, and others are under development. Although adverse side effects currently preclude use in otherwise healthy individuals, drugs that target the mTOR pathway could one day become widely used to slow ageing and reduce age-related pathologies in humans.

Date: 2013
References: Add references at CitEc
Citations: View citations in EconPapers (9)

Downloads: (external link)
https://www.nature.com/articles/nature11861 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:493:y:2013:i:7432:d:10.1038_nature11861

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature11861

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().